glp-1 receptor agonist brands Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Patents and regulatory exclusivities on

The legal action against Hims would be just another addition to the pile of 100+ suits the company has filed against compounders amid a mounting number of GLP-1 dramas

31 However, a causal relationship has not been established

Scientific Reference 2: Wilding et al., New England Journal of Medicine (2021) 2

Additionally, individuals with impaired glucose control may benefit from its glucose-lowering effects, while those with excess liver fat could see improvements in hepatic metabolism

Dual and Triple Agonists: The next generation of medications, such as Tirzepatide (which targets both GLP-1 and GIP receptors), are already demonstrating even greater efficacy for weight loss and blood sugar control

Always consult your provider before purchasing medications from outside traditional pharmacies